- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00465270
Patent Foramen Ovale Closure or Medical Therapy After Stroke - RESPECT Trial
Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment (RESPECT)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Accès étendu
Contacts et emplacements
Lieux d'étude
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 2T9
- University Of Calgary
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta
-
-
British Columbia
-
New Westminster, British Columbia, Canada, V3L 3W5
- Royal Columbian Hospital
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital
-
Vancouver, British Columbia, Canada, V5Z 1Y6
- St. Paul's Hospital
-
-
Ontario
-
London, Ontario, Canada, N6G 2V2
- Stroke Prevention & Atherosclerosis Research Center (SPARC) - Robarts Research Institute
-
Toronto, Ontario, Canada, M5G 2C4
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Montreal Heart Institute
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35249
- University of Alabama
-
-
Arizona
-
Scottsdale, Arizona, États-Unis, 85259
- Mayo Clinic
-
-
California
-
Los Angeles, California, États-Unis, 90095
- UCLA
-
Los Angeles, California, États-Unis, 90033
- LAC + USC Medical Center
-
Oakland, California, États-Unis, 94609
- Summit Medical Center
-
San Diego, California, États-Unis, 92123
- Sharp Memorial Hospital
-
San Francisco, California, États-Unis, 94115
- Kaiser Permanente
-
-
Colorado
-
Denver, Colorado, États-Unis, 80262
- University of Colorado
-
Littleton, Colorado, États-Unis, 80120
- South Denver Cardiology Associates
-
Loveland, Colorado, États-Unis, 80538
- Medical Center of the Rockies
-
-
District of Columbia
-
Washington, District of Columbia, États-Unis, 20010
- Washington Hospital Center
-
Washington, District of Columbia, États-Unis, 20037
- George Washington University Hospital
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32204
- St. Vincent's Medical Center
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637-1470
- University of Chicago
-
Chicago, Illinois, États-Unis, 60611-3078
- Northwestern University
-
Palos Heights, Illinois, États-Unis, 60463
- Neurologic Associates Inc
-
Peoria, Illinois, États-Unis, 61637
- OSF St. Francis Medical Center
-
Springfield, Illinois, États-Unis, 62702
- Southern Illinois University Neurology
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46237
- Indiana Heart Physicians
-
-
Iowa
-
Des Moines, Iowa, États-Unis, 50314
- Ruan Neurology
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa Hospitals and Clinics
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- Kansas University Medical Center
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40536
- University of Kentucky
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Towson, Maryland, États-Unis, 21014
- Midatlantic Cardiovascular Associates
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109-0316
- University of Michigan Health System
-
-
Minnesota
-
Duluth, Minnesota, États-Unis, 55805
- St. Mary's Duluth Clinic
-
Minneapolis, Minnesota, États-Unis, 55455
- University of Minnesota
-
Minneapolis, Minnesota, États-Unis, 55407
- Abbott Northwestern Hospital
-
Saint Louis Park, Minnesota, États-Unis, 55426
- Methodist Hospital/Park Nicollet Medical Center
-
-
Missouri
-
Saint Louis, Missouri, États-Unis, 63110
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68198-2045
- University of Nebraska Medical Center
-
-
New Jersey
-
Cherry Hill, New Jersey, États-Unis, 08034
- Our Lady of Lourdes Medical Center
-
Newark, New Jersey, États-Unis, 07103
- University of Medicine and Dentistry of New Jersy
-
-
New York
-
Albany, New York, États-Unis, 12208
- Albany Medical Center
-
Amherst, New York, États-Unis, 14226
- Dent Neurologic Institute
-
Rochester, New York, États-Unis, 14642
- University of Rochester
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Duke University Medical Center
-
Greensboro, North Carolina, États-Unis, 27410
- Moses H. Cone Memorial Hospital
-
-
Ohio
-
Akron, Ohio, États-Unis, 44320
- Neurology and Neuroscience Associates
-
Cleveland, Ohio, États-Unis, 44106
- University Hospitals of Cleveland
-
Columbus, Ohio, États-Unis, 43210
- Ohio State University
-
-
Oregon
-
Portland, Oregon, États-Unis, 97225
- Providence St. Vincent's Medical Center
-
Portland, Oregon, États-Unis, 97329
- Oregon Stroke Center, OHSU
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18105
- Lehigh Valley Hospital
-
Hershey, Pennsylvania, États-Unis, 17033
- Penn State Milton South Hershey Medical Center
-
Lancaster, Pennsylvania, États-Unis, 17543
- Lancaster General Hospital
-
Langhorne, Pennsylvania, États-Unis, 19067
- St. Mary's Medical Center
-
-
South Carolina
-
Charleston, South Carolina, États-Unis, 29425
- Medical University of South Carolina
-
-
South Dakota
-
Sioux Falls, South Dakota, États-Unis, 57108
- North Central Heart Institute
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232-8802
- Vanderbilt University
-
Nashville, Tennessee, États-Unis, 37205
- St. Thomas Neurology
-
-
Texas
-
Dallas, Texas, États-Unis, 75390-8897
- UT Southwestern Medical School
-
Houston, Texas, États-Unis, 77030
- University of Texas Houston Health Science Center
-
-
Virginia
-
Virginia Beach, Virginia, États-Unis, 23454
- Sentara Virginia Beach General Hospital
-
-
Washington
-
Seattle, Washington, États-Unis, 98104
- UW Medicine Stroke Center
-
-
West Virginia
-
Charleston, West Virginia, États-Unis, 25304
- Charleston Area Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin Hospital
-
Marshfield, Wisconsin, États-Unis, 54449
- Marshfield Clinic
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subjects who have had a cryptogenic stroke within the last 270 days
- Subjects who have been diagnosed with a Patent Foramen Ovale (PFO)
- Subjects willing to participate in follow-up visits
Exclusion Criteria:
- Subjects with intracardiac thrombus or tumor
- Subjects who have an acute or recent (within 6 months) myocardial infarction or unstable angina
- Subjects with left ventricular aneurysm or akinesis
- Subjects with atrial fibrillation/atrial flutter (chronic or intermittent)
- Subjects with another source of right to left shunt identified at baseline, including an atrial septal defect and/or fenestrated septum
- Subjects with contraindication to aspirin or Clopidogrel therapy
- Pregnant or desire to become pregnant within the next year
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Device
AMPLATZER PFO Occluder
|
patent foramen ovale closure device
|
Comparateur actif: Standard or Care - Medical Management
Medical treatment with Aspirin alone, Coumadin alone, Clopidogrel alone, or Aspirin combined with dipyridamole.
|
Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Composite of Recurrent Nonfatal Ischemic Stroke, Fatal Ischemic Stroke, or Early Death After Randomization
Délai: Trial enrollment was stopped once 25 unique subjects were mutually adjudicated by the CEC and DSMB as having experienced a primary endpoint event. This occurred on December 20, 2011. The mean follow-up time was 2.6 years.
|
Nonfatal stroke is defined as: focal neurological deficit presumed to be due to focal ischemia, and either 1) symptoms persisting 24 hours or greater, or 2) symptoms persisting less than 24 hours but associated with MR or CT imaging findings of a new, neuroanatomically relevent, cergral infarct. Post-randomization death is defined as: in the MM group as all-cause mortality within 45 days after randomization, and in the device group as all-cause mortality 30 days after implant or 45 days after randomizaiton, whichever occurs last. |
Trial enrollment was stopped once 25 unique subjects were mutually adjudicated by the CEC and DSMB as having experienced a primary endpoint event. This occurred on December 20, 2011. The mean follow-up time was 2.6 years.
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Rate of Complete PFO Closure (Assessed by TEE Bubble Study) at the 6-month Follow-up in the Device Group
Délai: 6 months
|
6 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Jeffrey Saver, MD, UCLA Stroke Center
- Chercheur principal: John D Carroll, MD, University of Colorado, Denver
- Chercheur principal: Richard Smalling, MD, University of Texas Houston Health Science Center
- Chercheur principal: David Thaler, MD, Tufts Medical Center
Publications et liens utiles
Publications générales
- Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017 Sep 14;377(11):1022-1032. doi: 10.1056/NEJMoa1610057.
- Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med. 2013 Mar 21;368(12):1092-100. doi: 10.1056/NEJMoa1301440.
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- AGA-006
- G990318
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur AMPLATZER PFO Occluder
-
SeptRx, Inc.InconnueMalformations septales cardiaques | Malformations cardiaques congénitales | Foramen ovale, brevetAllemagne, France
-
Hangzhou Dinova EP Technology Co., LtdPas encore de recrutementForamen ovale perméableChine
-
China National Center for Cardiovascular DiseasesRecrutement
-
Lifetech Scientific (Shenzhen) Co., Ltd.Recrutement
-
Coherex MedicalRésiliéPatients souffrant de migraine et de FOP
-
Encore Medical Inc.Bright Research Partners; Yale Cardiovascular Research GroupRecrutementForamen ovale perméable | AVC cryptogéniqueÉtats-Unis
-
Lifetech Scientific (Shenzhen) Co., Ltd.RetiréForamen ovale perméable | AVC cryptogéniqueChine
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecrutementForamen ovale perméable | FOPPologne
-
Chinese University of Hong KongPamela Youde Nethersole Eastern HospitalActif, ne recrute pas
-
Abbott Medical DevicesApprouvé pour la commercialisationForamen ovale perméable | FOP